ArticleCancer immunology, immunotherapy : CII2025
VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- HIF inhibition: Current strategies and clinical challenges.Redox biology · 2026Review
- MT1G promotes the progression of ccRCC by suppressing ferroptosis through activation of the PI3K-AKT pathway.Translational oncology · 2026Article
- Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.International journal of molecular sciences · 2026Review
- Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies.International journal of molecular sciences · 2026Review
- The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026Review
- IFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis.Research (Washington, D.C.) · 2026Article
- Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe von Hippel-Lindau (VHL) gene is frequently mutated in clear cell renal cell carcinoma (ccRCC) which results in stabilization of hypoxia-inducible factor (HIF). Despite the well-known immunosuppressive effect of HIF, ccRCC is considered an immunogenic tumor with high lymphocyte infiltration. Since NK cells have a prognostic value in ccRCC patients, it is important to understand how VHL mutations affect NK cell activity and anti-tumor immunity.
methodsTumor spheroids were generated from parental 786-O (VHL-mutated) and 786-O-pVHL (VHL-restored) ccRCC cell lines. Tumor phenotypes, proteome, and secretome were analyzed by flow cytometry, mass spectrometry, and Luminex assays, respectively. Quantitative proteomics analysis and quantitative gene ontology enrichment were used to correlate protein expression changes to ccRCC progression and immunosuppressive pathways. NK cell infiltration, activation, and cytotoxicity were assessed in co-cultures of ccRCC spheroids with NK cells from healthy donors using real-time imaging, immunostaining, and flow cytometry, respectively.
resultsVHL-mutated tumor spheroids were significantly less infiltrated by NK cells compared with VHL-restored tumor spheroids. pVHL-infiltrating NK cells showed an activated phenotype along with the ability to reduce tumor spheroid size. Proteomic analysis revealed that VHL-restored tumors express reduced levels of proteins associated with ccRCC progression and immunosuppression, including components of MHC class I processing and PD-1 signaling. Furthermore, VHL-restored tumors exhibited decreased levels of hypoxia-related and pro-tumoral cytokines, such as GROα, IL-8, IL-10, TRAIL, VEGF, and SCF. Within 768-O tumor spheroids, NK cells displayed a higher degree of hypoxia and expression of HIF1α, and inhibition of HIF1α resulted in higher NK cell infiltration into 786-O spheroids. Similarly, inhibition of the VHL-target gene, HIF2α, in 786-O spheroids resulted in increased NK cell infiltration.
conclusionsVHL mutant tumors are less infiltrated by NK cells due to immunosuppressive pathways driven by HIF stabilization. Restoration of VHL reprograms the tumor microenvironment, reducing ccRCC progression and immunosuppressive signaling while enhancing NK cell infiltration and activation. Inhibition of HIFα improves NK cell infiltration into VHL mutant tumors. Therefore, inhibition of HIFα should be explored as a therapeutic strategy in ccRCC to improve NK cell anti-tumor efficacy against VHL-mutated tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.